Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Recruiting

Phase 2

NaxitamabNaxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Sponsor:

Giselle Sholler

Code:

NCT05489887

Conditions

High-risk Neuroblastoma

Eligibility Criteria

Sex: All

Age: 12 - 21

Healthy Volunteers: Not accepted

Interventions

Naxitamab

Ceritinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by Giselle Sholler on 2024-12-04.